My Market Wizard

GSK plc 6-K Analysis & Summary – 2/21/2025

⚠️This is not investment advice.

⚠️ This is an experimental project and this report is for informational purposes only and should not be considered investment advice. Conduct your own thorough research and consult with a qualified financial advisor before making any investment decisions. ⚠️

GSK plc

Filing date:

02/21/2025

TLDR:

Tony Wood, Chief Scientific Officer of GSK plc, received a cash payment related to vested shares under the GlaxoSmithKline Deferred Investment Award Programme.

ELI5:

A top executive at GSK, Tony Wood, received a payment as part of a company program where he was awarded shares that have now become available to him. He received cash instead of the actual shares after taxes were taken out.

Accession #:

0001654954-25-001744

Published on

Analyst Summary

  • Tony Wood, Chief Scientific Officer, received a cash payment of £247,942.28 less applicable tax withholding.
  • The payment relates to the vesting of 50% of an award made on 18 February 2021 under the GlaxoSmithKline Deferred Investment Award Programme.
  • The transaction involved 17,182.417 notional Ordinary Shares.
  • The price per share was £14.4300.
  • The transaction date was February 18, 2025.

Potential Implications

Stock Price

  • The transaction is unlikely to have a significant impact on the stock price as it relates to an internal compensation program for an executive.

⚠️ This is an experimental project and this report is for informational purposes only and should not be considered investment advice. Conduct your own thorough research and consult with a qualified financial advisor before making any investment decisions. ⚠️